StockData
Pharvaris N.V. logo

Pharvaris N.V. (PHVS) stock

PHVSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 20-F on Apr 2, 2026Score 4/30
$33.83−0.35 (-1.02%)

Close on Nov 12, 2026Market cap $2.21BP/E –Yield –

Earnings

Pharvaris's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
–
Not yet scheduled
Revenue, Q2 FY2023
–
EPS, Q2 FY2023
0.63 EUR
Latest guidance
None
No outlook given in releases

Quarterly results

Revenue and earnings per share from each of Pharvaris's earnings releases, newest first

QuarterReportedRevenueYoYEPSSource
Q2 FY2023ended Jun 30, 2023Aug 7, 2023before the open––0.63 EURRelease
Q2 FY2022ended Jun 30, 2022Sep 12, 2022before the open–––Release
Q4 FY2021ended Dec 31, 2021Mar 29, 2022before the open–––Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Guidance

Pharvaris has not given guidance in its releases

Many companies give their outlook only on the conference call or not at all. When Pharvaris puts a forecast in an earnings release, it is listed here with the exact sentence.

Press releases

Releases Pharvaris filed with the SEC as exhibits to Form 8-K or 6-K

  1. Pharvaris Reports Third Quarter 2026 Financial Results and Provides Business Update
    6-K
  2. Management’s Discussion and Analysis of Financial Condition and Results of Operations
    6-K
  3. Unaudited Condensed Consolidated Interim Financial Statements
    6-K
  4. 6-K exhibit EX-99.1
    6-K
  5. Pharvaris Announces Positive Topline Data from CHAPTER-3 Pivotal Study of Deucrictibant XR for Prophylaxis of HAE Attacks
    6-K
  6. Pharvaris Reports Second Quarter 2026 Financial Results and Provides Business Update
    6-K
  7. Management’s Discussion and Analysis of Financial Condition and Results of Operations
    6-K
  8. Unaudited Condensed Consolidated Interim Financial Statements
    6-K
  9. Pharvaris Announces Annual General Meeting of Shareholders
    6-K
  10. The agenda for the AGM is as follows:
    6-K
  11. acting on behalf of (only to be completed if relevant)
    6-K
  12. Pharvaris Reports First Quarter 2026 Financial Results and Provides Business Update
    6-K
  13. Management’s Discussion and Analysis of Financial Condition and Results of Operations
    6-K
  14. Unaudited Condensed Consolidated Interim Financial Statements
    6-K
  15. Pharvaris Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
    6-K

See a number that looks wrong?